Cross-referencing shows that anti-human monoclonal antibodies targeting the AXL receptor tyrosine kinase inhibit AXL activity effectively, limiting the proliferation and migration of pancreatic cancer cells in vitro and in vivo (Leconet et al., 2014). The gene discussed is AXL; the disease is pancreatic neoplasm.